UpFront

Contributed by:

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Market Report U.S. Prescription Sales Grow U.S. sales of ethical ­pharmaceuticals and insulins through retail and non-retail channels grew 5.1% in 2009, reaching $300.3 billion, ­compared with growth of 1.8% in 2008. While the 32 innovative products launched last year brought important new treatment options to patients in a number of disease areas, including cancer, ­thrombosis, and atrial ­fibrillation, they drove only a limited increase in drug spending. Factors contributing to growth include: n Stronger demand for ­prescription drugs despite macroeconomic conditions; Dispensed prescription ­volume in retail channels grew at a 2.1% pace, to 3.9 billion dispensed ­prescriptions, up from 1.0% growth in 2008. Although the volume of new therapy starts in 17 major chronic disease areas declined by about 1%, the volume of add-on therapy starts, switches, and refills rose by almost 2% last year; n Sustained pricing practices by pharmaceutical ­manufacturers, competing on the basis of clinical ­evidence and value; n Inventory management actions taken by retail ­pharmacies at the beginning of 2009 to bring stocking levels in line with market demand; n Greater use of specialty ­pharmaceuticals — a class of medications used to treat complex, chronic conditions — which now comprise 21% of U.S. market value and grew 7.5% last year. R&D Spending R&D Investment by U.S. Companies Increases Research & development (R&D) investment in new medicines and vaccines by the U.S. biopharmaceutical industry was $65.3 billion in 2009, an increase of more than $1.5 ­billion from the total R&D investment made in 2008, according to a combined ­analysis conducted by Burrill & Company and Pharmaceutical Research and Manufacturers of America (PhRMA). PhRMA-member ­companies alone spent about $45.8 billion on R&D last year, according to a PhRMA survey. The Burrill & Company analysis shows that non-PhRMA ­pharmaceutical research ­companies in the United States spent an estimated $19.5 ­billion on R&D in 2009. Tuning in… Featured Podcasts Market Research: Changing Dynamics Featured Thought Leaders: Lynnette Cooke, Kantar Health, Dr. Debbie Kossman, PMRG, Juliana Mastroserio, Johnson & Johnson Scientist versus Salesman: Which Approach Will Enable Your Sales Reps to Raise Their Value to the Industry? Featured Thought Leader: Tim Ryan, Boehringer Ingelheim Leveraging Expanded Access and Named Patient Programs Featured Thought Leader: Nicky Wisener, Idis Featured Whitepapers Using Conjoint Analysis To Maximize Your Clinical Research Designs Provided by: Answers & Insights Market Research, Inc. Evolution in action: As Markets and Medicine Evolve, ­Pharmaceutical Sales Models and Deployment Strategies Must Keep Up, for the Sake of Survival Provided by: BioPath Consulting A New Decade Means New Challenges for Patient ­Education: a whitepaper by Cutting Edge Information Provided by: Healthy Advice Networks Awards CommonHealth Wins DTC Awards EvoLogue, a full-service consumer agency of ­CommonHealth providing insight-driven behavioral-marketing ­services, has won four DTC National Advertising Awards. EvoLogue earned Gold and Bronze awards for two different women’s ­healthcare brands in the Best Point-Of-Care ­Campaign category, Silver for Best Branded ­Integrated Campaign, and Bronze for Best Branded Print Campaign. Purohit ­Navigation Wins DxMA Awards Purohit Navigation won six awards at the 2010 Diagnostic Marketing Association (DxMA) ­Creative Communications Awards ceremony, which honors the best of the best in diagnostic marketing. The agency won three first-place awards, two ­second-place awards, and a third-place honor. Roche Scientist Honored Roche Scientist Kyle Kolaja, Ph.D., was recently named a Fellow of the Academy of Toxicological Sciences (ATS). To earn the certification, Dr. Kolaja, Director of Early Safety and ­Investigative Toxicology in Roche’s Non-Clinical ­Safety, had to demonstrate impressive professional experience, extensive knowledge of toxicology and involvement in broad-based toxicological ­activities. He is among the youngest ATS Fellows and is the first Roche scientist to achieve this recognition since 1995. The author of almost 50 peer-reviewed scientific papers, Dr. Kolaja is the recipient of a number of grants and awards and is a member of several ­professional organizations, including being a ­Diplomate of the American Boards of Toxicology. Social Media Opportunities for ­Pharma Exist in Social Media Social media participation drives a more engaged patient, according to a new study from marketing services company Epsilon. Among Internet users, product/health Web sites are as important as healthcare provider ­interactions when it comes to gaining relevant health ­information. In addition, ­consumers are finding ­comfort and answers through their social media interactions. Key findings include: n 40% of online consumers use social media for health information (reading or posting content), but ­frequency of engagement varies widely; n Individuals who use ­healthcare social media fall into two broad groups; the highly engaged patient who takes an active role in health management (80%) versus individuals who lack confidence to play an active role in their own health (80%). n Consumers engage with healthcare social media for both rational and emotional reasons. Many healthcare social media users want reassurance, support, and a sense of intimacy from people who are going through a similar ­experience. Social media users are searching for foundational information about their specific ­conditions and symptoms, information about drugs and supplements, and the latest health news. n Lack of participation in social media is both a time and trust issue: Reliance on a doctor’s advice was the most commonly cited reason. Other consumers said they don’t have the time to use social media, or simply don’t trust the information they find. n Third-party health-related sites are the ­important destinations for both social and editorial content, but their level of credibility varies; n Many people have mixed feelings about how ­pharmaceutical ­companies should ­participate in Web sites and social media, but most are open to some level of participation, as long as it is transparently disclosed. Sales Rep Access Physicians Requiring Appointments Increase About 98% of physicians say their offices are visited by up to 20 sales reps each week from the pharmaceutical or medical-device industries, with almost half of the physicians surveyed saying they require or prefer appointments to be made by reps before one-on-one meetings, according to SK&A, a Cegedim Company. The percentage of ­physicians who require or ­prefer appointments has increased significantly in the past year, from 38.5% in December 2008 to 49.6% in December 2009. The number of physicians who restrict access altogether has remained unchanged in the past 12 months at about 23%. Other trends include: n Specialty physicians are less likely to grant sales reps access than general ­practitioners. The top-three accessible physicians are allergists/immunologists (4.4% no-see rate), diabetes specialists (7%) and ­gynecologists (7.5%). The least accessible physicians are diagnostic radiologists (91.8% no-see rate), ­pathologists (91.7%), and neuroradiologists (91.5%). n Offices with fewer patients seen daily are less likely to host sales reps. Sites with a daily patient volume of one to 10 have a no-access rate of 28.9% and those with a daily patient volume of 31 to 40 have a 13.6% no-access rate. n Health system- and hospital-owned offices are less likely to grant sales reps access than offices not part of a health system or owned by a hospital. Health system and hospital-owned offices have no-access rates of 30.3% and 29.5%, respectively. Nonhealth system and ­hospital-owned offices have no-access rates of 21.5% each. n Larger practices are less likely to grant sales reps access. Offices with one to two physicians have a no-access rate of 13.4% while offices with 10 or more physicians have a no access rate of 42.1%. n Physician offices in the ­Western U.S. are least likely to allow sales reps access. The South had the lowest no-access rate with 19.4%, and the West had a 28.2% no-access rate. Therapeutic Update Key Trends … IMS Health identified the following key trends among the major therapy areas: n Antipsychotics remained the top-selling class of medications in the U.S., with 2009 prescription sales of $14.6 billion, equal to the 2008 level. n Lipid regulators continued as the largest therapy class in the U.S. by dispensed prescription volume, growing at a 5% pace to 212 million prescriptions dispensed in 2009. Sales of lipid regulators declined 10% last year to $13.1 billion, reflecting an ongoing shift toward lower-cost generic alternatives. Lipid regulators ranked No. 3 in overall sales in 2009. n Proton pump inhibitors replaced lipid regulators as the second-largest therapeutic class in sales last year. Proton pump inhibitors sales totaled $13.6 billion, a 2% decline year over year, while ­dispensed prescription volume for this therapeutic class rose 5%. n Antidepressants became the fourth-largest class in 2009, up from its No. 5 ranking the prior year, with U.S. prescription sales growth of 3% to $9.9 billion.

Posted in:

Post a Comment

You must be logged in to post a Comment.

FEEDBACK